These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12827827)

  • 1. [Cardiac rehabilitation: a plus value for secondary prevention?].
    Scardi S; Mazzone C
    Monaldi Arch Chest Dis; 2003 Mar; 60(1):1-6. PubMed ID: 12827827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network.
    Giannuzzi P; Temporelli PL; Marchioli R; Maggioni AP; Balestroni G; Ceci V; Chieffo C; Gattone M; Griffo R; Schweiger C; Tavazzi L; Urbinati S; Valagussa F; Vanuzzo D;
    Arch Intern Med; 2008 Nov; 168(20):2194-204. PubMed ID: 19001195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary prevention for patients following a myocardial infarction: summary of NICE guidance.
    Skinner JS; Cooper A; Feder GS;
    Heart; 2007 Jul; 93(7):862-4. PubMed ID: 17569811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving outcomes after acute coronary syndrome with rehabilitation and secondary prevention.
    Briffa T; Chow CK; Clark AM; Redfern J
    Clin Ther; 2013 Aug; 35(8):1076-81. PubMed ID: 23973041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year multicomprehensive secondary prevention program: favorable effects on cardiovascular functional capacity and coronary risk profile after acute myocardial infarction.
    Giallauria F; Lucci R; D'Agostino M; Vitelli A; Maresca L; Mancini M; Aurino M; Del Forno D; Giannuzzi P; Vigorito C
    J Cardiovasc Med (Hagerstown); 2009 Oct; 10(10):772-80. PubMed ID: 19531961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Secondary prevention after myocardial infarction].
    Czuriga I
    Orv Hetil; 2002 Sep; 143(37):2117-28. PubMed ID: 12434627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical management after myocardial infarction: an evidence-based perspective.
    Sharpe N
    Br J Clin Pract Suppl; 1996 Jul; 84():25-30. PubMed ID: 8994999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice.
    Heeley E; Anderson C; Patel A; Cass A; Peiris D; Weekes A; Chalmers J
    Int J Stroke; 2012 Dec; 7(8):649-54. PubMed ID: 21978147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of risk factor modification through cardiac rehabilitation.
    Borrás IC; Cruz-Jiménez M; Nadal E; Middelhoff A; Rivera A
    Bol Asoc Med P R; 2008; 100(4):75-9. PubMed ID: 19400532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice].
    Garnier LF
    Ann Cardiol Angeiol (Paris); 1997 Oct; 46(8):507-12. PubMed ID: 9538362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Secondary prevention after myocardial infarction].
    Vacheron A; Bounhoure JP;
    Bull Acad Natl Med; 2007 Nov; 191(8):1763-77. PubMed ID: 18666472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
    Tanguay JF
    Adv Cardiol; 2012; 47():20-30. PubMed ID: 22906900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac rehabilitation and risk factor management after myocardial infarction. Clinical and economic evaluation.
    Oldridge NB
    Wien Klin Wochenschr; 1997; 109 Suppl 2():6-16. PubMed ID: 9286070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in secondary prevention after acute myocardial infarction: A call for action.
    Piepoli MF; Corrà U; Dendale P; Frederix I; Prescott E; Schmid JP; Cupples M; Deaton C; Doherty P; Giannuzzi P; Graham I; Hansen TB; Jennings C; Landmesser U; Marques-Vidal P; Vrints C; Walker D; Bueno H; Fitzsimons D; Pelliccia A
    Eur J Prev Cardiol; 2016 Dec; 23(18):1994-2006. PubMed ID: 27600690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction.
    West RR; Jones DA; Henderson AH
    Heart; 2012 Apr; 98(8):637-44. PubMed ID: 22194152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
    BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients after their first myocardial infarction.
    Flapan AD
    BMJ; 1994 Oct; 309(6962):1129-34. PubMed ID: 7987108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.